TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Adjusted Mean Change From Baseline in HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Successful response to treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfactory Sexual Episodes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prevalence of high grade cardiac arrhythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Decision to delivery interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Free
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nutritional Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of participants with virologic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Progression-free Survival (PFS) Time
Endpoint domain: Mortality/survival
Primary endpoint: Bone microarchitecture results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Vitamin D serum concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Unnecessary admission rate
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Toxicity of the combination therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in nursing home quality indicators
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Technical Success of PUG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of anti-SARS-CoV-2 IgM and IgG antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Experiencing New or Increased FLS
Endpoint domain: Adverse events/effects
Primary endpoint: Safety and Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Observed Concentration (Cmax) of BGF MDI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinity (AUCinf) of BGF MDI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Curve From Time Zero to the Time of Last Quantifiable Concentration (AUClast) of BGF MDI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective response rate of intracranial lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Physical Activity sessions performed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Achieving Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Selectivity of stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Training performance gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to training regimen
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence of anastomotic leak
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in plasma HIV-1 RNA level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in plasma CD4 cell count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Major event-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Optimal P2Y12 reactive units (PRU) cut-off value of platelet inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Occurrences of Protocol-Defined Influenza-Like Illness (ILI)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Experience at Least One Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in the Growth Rate of Abdominal Aortic Aneurysm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Symptoms assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction of neuropathic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Stem cell engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Treatment Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Tinetti Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Edmonton Frail Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Sling / Fall Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Safety measured by dose-limiting toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Vital status of heart transplant recipient
Endpoint domain: Mortality/survival
Primary endpoint: Infection leading to hospitalization
Endpoint domain: Adverse events/effects
Primary endpoint: successful endotracheal intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Safety as measured by Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Gap in antibiotic therapy duration adherence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of Patients Achieving > or = 5% Weight Loss From Baseline to Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of Patients Maintaining > or = 5% Weight Loss at Week 104
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Composite endpoint of numbers of death or liver transplantation
Endpoint domain: Mortality/survival
Primary endpoint: Number of hospitalizations with liver related complications
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Prevalence of dynamic hyperinflation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Absolute Change From Baseline In High-density Lipoprotein (HDL) Cholesterol Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Absolute Change From Baseline In HDL Particle Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Absolute Change From Baseline In HDL Particle Number
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of discontinuation of Betaferon
Endpoint domain: Adverse events/effects
Primary endpoint: Detect of the reactive dose (RD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number Alive at Hospital Discharge
Endpoint domain: Mortality/survival
Primary endpoint: Frequency of Impulsive Aggression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Minute Ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in gait evaluation rating scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Subjects Achieving PASI75 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Intraocular Pressure Within Normal Limits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Area Under the Time Corrected Endogenous Creatinine Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Serology test results for COVID-19
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Difference in microparticle levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the number of foods eaten
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Corneal Incision Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Task accuracy from the behavioral response during the active, auditory oddball ERP test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reaction time from the behavioral response during the active, auditory oddball ERP test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional assessments as derived from the Brief Assessment of Cognition in Schizophrenia (BACS)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Ease of use of the overall procedure
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time of procedure
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Endoscopic Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Pathological Complete Response rate (pCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Peak serum IGF-1 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change From Baseline in Total 5 Symptom Score (T5SS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of Oxaliplatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical Function in Intensive Care Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chelsea Critical Care Physical Assessment Tool
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Premorbid Level of Activity Scales
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Opioid overdose - fatal and nonfatal
Endpoint domain: Mortality/survival
Primary endpoint: Time to definitive diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Amount of LNS formulation consumed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preference for LNS formulations
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Acceptability of feeding LNS
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Participants Alive and Free of Respiratory Failure at Day 28
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of early allograft dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of primary non function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in the CDR-SB at 18 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients achieving PASI Score of 90
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Proportion of Patients Euthyroid Through Gestation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Quality of recovery (QoR) score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Symptoms of lymphedema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safety of MRTX849
Endpoint domain: Adverse events/effects
Primary endpoint: clinical activity/efficacy of MRTX849
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes in physical health
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Changes in mental health
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Swedish Acceptance and Action Questionnaire (SAAQ)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Systolic blood pressure (SBP) between baseline and 3rd month
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Systolic blood pressure (SBP) between 3rd month and 6th month
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in diastolic blood pressure (DBP) between baseline and 3rd month
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinical remission rate of obstructive jaundice
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occupational stress measured by Nursing stress scale (NSS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Coping skills measured by The Brief Coping Orientations to Problems Experienced (COPE) Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Caregiver QOL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Declination of glomerular infiltration rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Strut coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: In stent late lumen loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in optic nerve sheath diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Clinical Cure (PGA Score = 0 or 1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment Success for the Target Lesion (TLSS Score of 0 or 1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Knee Pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Accuracy of classification of motor symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of detection of medication timing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Deaths
Endpoint domain: Mortality/survival
Primary endpoint: Overall Cleanliness of the Prep
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in gene expression in the adipose tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Efficacy of Susanna implant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of Susanna implant
Endpoint domain: Adverse events/effects
Primary endpoint: Endometrial Hyperplasia Resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Left Ventricular Hypertrophy Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent heavy drinking days
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Per-patient detection sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Per-lesion detection sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-discharge growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite measure of Absorption, Metabolism and Excretion of Phytochemicals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Disease Control Rate (DCR)
Endpoint domain: Mortality/survival
Primary endpoint: Composite THINC-it Tool Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Difference in DNA methylation patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in microbiota composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in T cell phenotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change BNP/NT-pro BNP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in NYHA class
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Isolation of circulating tumoral cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: changes in plasma 25(OH)D concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Change in Number of Points Seen on the Leicester Peripheral Field Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AFS score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Frequency and incidence rate of complications
Endpoint domain: Adverse events/effects
Primary endpoint: Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GI.1 VLP Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Blocking Titer (GMBT50) of Anti-norovirus GII.4 VLP Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Ongoing pregnancy per embryo transfer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: IGA success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Sympathetic Cardiac Innervation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of overall KOOS
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in pain survey results from baseline
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Number of Participants With Adverse Events Related to AVI-4568
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Injection Site Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Clinically Significant Change From Baseline in Laboratory Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Father-Baby Attachment Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of sunken scars
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Low density Lipoprotein cholesterol level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in liver fibrosis stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Markers of inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Clinically Significant Changes in Cardiac Function As Determined by Left Ventricular Ejection Fraction (LVEF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Daily time of moderate physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily time of inactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of dose-limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Nature of dose-limiting toxicities (DLTs) graded per NCI CTCAE v4.0
Endpoint domain: Adverse events/effects
Primary endpoint: ambulatory blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma nitrite levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area Under the Concentration-Time Curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impact of mouth wash on PEG insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myocardial Injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hormonal changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: pharmacokinetic profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Had Treatment-Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Had Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Progression-Free Survival (PFS) at 2 Years
Endpoint domain: Mortality/survival
Primary endpoint: Overall Survival (OS) Rate at 2 Years
Endpoint domain: Mortality/survival
Primary endpoint: CD3, CD4, CD8 counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Quality of life measured by short-form36
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: EEG results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: cumulative morphine consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Average percentage of hair reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activities of Daily Living (ADL) scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: plaque accumulation (ΔR30)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ASRS Responder Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported effects
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status